Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Airbnb has a plan to fix cleaning fees
Saudi viewers angry over apparent ban on World Cup streaming
THE BEST BLACK FRIDAY DEAL YET (Ad)
Walmart shooting claims teen, young woman, father, mother
Cuba's informal market finds new space on growing internet
THE BEST BLACK FRIDAY DEAL YET (Ad)
Bird flu prompts slaughter of 1.8M chickens in Nebraska
US-England World Cup game seen by 19.98M on US television
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Airbnb has a plan to fix cleaning fees
Saudi viewers angry over apparent ban on World Cup streaming
THE BEST BLACK FRIDAY DEAL YET (Ad)
Walmart shooting claims teen, young woman, father, mother
Cuba's informal market finds new space on growing internet
THE BEST BLACK FRIDAY DEAL YET (Ad)
Bird flu prompts slaughter of 1.8M chickens in Nebraska
US-England World Cup game seen by 19.98M on US television
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Airbnb has a plan to fix cleaning fees
Saudi viewers angry over apparent ban on World Cup streaming
THE BEST BLACK FRIDAY DEAL YET (Ad)
Walmart shooting claims teen, young woman, father, mother
Cuba's informal market finds new space on growing internet
THE BEST BLACK FRIDAY DEAL YET (Ad)
Bird flu prompts slaughter of 1.8M chickens in Nebraska
US-England World Cup game seen by 19.98M on US television
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Airbnb has a plan to fix cleaning fees
Saudi viewers angry over apparent ban on World Cup streaming
THE BEST BLACK FRIDAY DEAL YET (Ad)
Walmart shooting claims teen, young woman, father, mother
Cuba's informal market finds new space on growing internet
THE BEST BLACK FRIDAY DEAL YET (Ad)
Bird flu prompts slaughter of 1.8M chickens in Nebraska
US-England World Cup game seen by 19.98M on US television
NASDAQ:CYCN

Cyclerion Therapeutics - CYCN Stock Forecast, Price & News

$0.79
-0.01 (-0.84%)
(As of 11/25/2022 08:57 PM ET)
Add
Compare
Today's Range
$0.78
$0.83
50-Day Range
$0.35
$1.00
52-Week Range
$0.35
$2.52
Volume
102,900 shs
Average Volume
202,611 shs
Market Capitalization
$34.23 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Cyclerion Therapeutics MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
1.02% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.77mentions of Cyclerion Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.16) to ($1.26) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.22 out of 5 stars

Medical Sector

1024th out of 1,044 stocks

Pharmaceutical Preparations Industry

500th out of 510 stocks

CYCN stock logo

About Cyclerion Therapeutics (NASDAQ:CYCN) Stock

Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018 for the treatment of disorders of the CNS. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Receive CYCN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cyclerion Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CYCN Stock News Headlines

Cyclerion Shares Rise After Spurned Bid for Assets
Cyclerion Rejects Unsolicited Proposal To Buy Its Assets
Cyclerion Therapeutics Inc
Cyclerion Therapeutics reports Q1 results
Cyclerion Therapeutics Inc(CYCN)
See More Headlines
Receive CYCN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cyclerion Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CYCN Company Calendar

Last Earnings
11/09/2021
Today
11/27/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/23/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CYCN
Fax
N/A
Employees
32
Year Founded
N/A

Profitability

Net Income
$-51,650,000.00
Net Margins
-2,551.69%
Pretax Margin
-3,073.42%

Debt

Sales & Book Value

Annual Sales
$3.94 million
Book Value
$0.38 per share

Miscellaneous

Free Float
37,753,000
Market Cap
$34.23 million
Optionable
Not Optionable
Beta
1.83

Key Executives

  • Dr. Peter M. Hecht Ph.D. (Age 58)
    CEO & Director
    Comp: $108.22k
  • Ms. Cheryl Gault (Age 42)
    Chief Operating Officer
    Comp: $513.43k
  • Ms. Anjeza Gjino (Age 39)
    CFO & Corp. Sec.
  • Dr. Todd Milne Ph.D.
    Sr. VP of External Innovation
  • Ms. Jessica Rennekamp
    Associate Director of Corp. Communications
  • Mr. Christopher Winrow Ph.D.
    Sr. Director of Clinical Devel. & Neuroscience Program Lead
  • Ms. Jennifer Chickering Ph.D.
    Sr. Director of Clinical Strategy













CYCN Stock - Frequently Asked Questions

How have CYCN shares performed in 2022?

Cyclerion Therapeutics' stock was trading at $1.72 at the start of the year. Since then, CYCN stock has decreased by 54.3% and is now trading at $0.7869.
View the best growth stocks for 2022 here
.

When is Cyclerion Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our CYCN earnings forecast
.

How were Cyclerion Therapeutics' earnings last quarter?

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) released its quarterly earnings data on Tuesday, November, 9th. The company reported ($0.26) EPS for the quarter, topping analysts' consensus estimates of ($0.35) by $0.09. The business had revenue of $0.35 million for the quarter, compared to the consensus estimate of $3 million. Cyclerion Therapeutics had a negative net margin of 2,551.69% and a negative trailing twelve-month return on equity of 149.84%.

What other stocks do shareholders of Cyclerion Therapeutics own?
What is Cyclerion Therapeutics' stock symbol?

Cyclerion Therapeutics trades on the NASDAQ under the ticker symbol "CYCN."

Who are Cyclerion Therapeutics' major shareholders?

Cyclerion Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (3.80%), Renaissance Technologies LLC (0.65%), Prelude Capital Management LLC (0.21%), Two Sigma Advisers LP (0.08%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Andreas Busch, Mark G Currie, Peter M Hecht, Peter M Hecht, Slate Path Capital Lp, Terrance Mcguire and William Huyett.
View institutional ownership trends
.

How do I buy shares of Cyclerion Therapeutics?

Shares of CYCN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cyclerion Therapeutics' stock price today?

One share of CYCN stock can currently be purchased for approximately $0.79.

How much money does Cyclerion Therapeutics make?

Cyclerion Therapeutics (NASDAQ:CYCN) has a market capitalization of $34.22 million and generates $3.94 million in revenue each year. The company earns $-51,650,000.00 in net income (profit) each year or ($1.09) on an earnings per share basis.

How can I contact Cyclerion Therapeutics?

Cyclerion Therapeutics' mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The official website for the company is www.cyclerion.com. The company can be reached via phone at (857) 327-8778 or via email at ir@cyclerion.com.

This page (NASDAQ:CYCN) was last updated on 11/28/2022 by MarketBeat.com Staff